NEXALIN TECHNOLOGY INC (NXL)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$1.40-10.26%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · NXL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 267.7% |
| Our one-year growth estimate | diamond | -26.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 294.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 43 industry peers
NXL — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-09-28
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on September 1, 2026, Nexalin Technology, Inc. (the “Company”) presented its plan of compliance to the Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) and requested continued listing on Nasdaq and an extension to demonstrate compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”)…
Why it matters: The HALO trial is a key test of Nexalin's U.S. device program. Enrollment would show progress toward trial results and an FDA filing.
Supportive ifNexalin or UCSD confirms that enrollment has begun in the planned 160-person trial.
Worry ifNexalin reports that enrollment has not begun, or that the trial is delayed or paused.
Why it matters: Nexalin has ongoing losses and has raised money through stock sales and a note. More funding deals may add shares or debt.
Worry ifA new filing reports another stock sale, convertible deal, or debt note to fund daily needs.
Less concerning ifThe next earnings report shows no new financing and states that cash covers planned operations.
Why it matters: At 30 devices, the distributor must build a local factory at its own cost. That step opens the path to device fees and electrode royalties.
Supportive ifThe distributor buys the first 30 devices and says factory work in Brazil has begun.
Worry ifDevice orders stall below 30, or the required factory is not set up after the 30-device mark.
Why it matters: The first order and pilot are the opening test of the South America deal. They can show whether the company can turn the deal into sales.
Supportive ifThe distributor places a binding order for 10 devices. The Brazil pilot starts within 90 days of the deal.
Worry ifThe order is not filled, or the pilot has not launched within 90 days of the deal.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$408 on $10,000 · ±4.1% | How much price usually moves either way. |
| Bad day | $1,202 loss on $10,000 · 12.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,652 loss on $10,000 · 96.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The company used a 1-for-30 reverse split to address a bid-price issue. A listing decision will show if that step met Nasdaq rules.
Worry ifNasdaq denies more time, sets a delisting date, or confirms the company still fails a listing rule.
Less concerning ifNasdaq keeps the company listed and says it meets the bid-price and other cited listing rules.